Neurochem - Research Activities
Eprodisate (KIACTA™) is under regulatory review for marketing approval by the ... Eprodisate (KIACTA™) has received orphan drug status in the United States, the ...Neurochem Withdraws Its Marketing Authorisation Application For Kiacta ...
The European Medicines Agency (EMEA) has been formally notified byNeurochem Luxco II SARL of its decision to withdraw the application fora centralised marketing ...Cash Problems for Bellus Health
Cash Problems for Bellus Health-The resumption of phase III trials for Kiacta will lead to a significant increase in research and development spending.